Timing Is Everything: CAR T for Follicular Lymphoma Timing Is Everything: CAR T for Follicular Lymphoma
CAR T-cell therapy is the best option for patients with relapsed/refractory follicular lymphoma, even though it comes with serious side effects.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 25, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

' We Need to Rethink Our Options': Lung Cancer Recurrence'We Need to Rethink Our Options': Lung Cancer Recurrence
Dr Mark Kris discusses the emerging issue of recurrence in the chest resulting from improved systemic therapies.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 24, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Is the FDA Pausing More Cancer Trials? It's Hard to Tell Is the FDA Pausing More Cancer Trials? It's Hard to Tell
Clinical trial holds delay therapies getting to market and may be on the rise in oncology. But there ' s a lot the public doesn ' t know about how often these holds happen and why.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 24, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Chronic Myelogenous Leukemia (CML): 5 Things to Know Chronic Myelogenous Leukemia (CML): 5 Things to Know
Advanced and emerging therapies in CML offer significantly improved survival. These five things to know will help elucidate potential pitfalls and pearls to successful management.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

AI in Cancer Care: Use, Understanding, and Responsibility AI in Cancer Care: Use, Understanding, and Responsibility
Dr Maurie Markman discusses the evolving world of artificial intelligence as it affects cancer care.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

FDA Approves New Bladder Cancer Drug FDA Approves New Bladder Cancer Drug
The first-in-class agent is approved alongside bacillus Calmette-Gu érin to treat certain non–muscle-invasive bladder cancers that do not respond to bacillus Calmette-Guérin alone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Is Osimertinib Better Alone or With Chemotherapy in NSCLC? Is Osimertinib Better Alone or With Chemotherapy in NSCLC?
A new study reveals that baseline EGFR mutations may be key to making the decision in the frontline setting.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Few Cancer Survivors Meet ACS Nutrition, Exercise Guidelines Few Cancer Survivors Meet ACS Nutrition, Exercise Guidelines
Only 4% of cancer survivors reported adhering to four key healthy lifestyle practices endorsed by the American Cancer Society.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Clinical Summary Source Type: news

Hair Loss: Experts Provide Recommendations on Oral Minoxidil Hair Loss: Experts Provide Recommendations on Oral Minoxidil
The authors " identified a need for expert-based guidelines for prescribing and monitoring LDOM use in hair loss patients. "MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2024 Category: Cancer & Oncology Tags: Dermatology News Source Type: news

Has Immunotherapy Found Its Place in Pancreatic Cancer? Has Immunotherapy Found Its Place in Pancreatic Cancer?
A new study suggested that adding nivolumab to neoadjuvant treatment improves outcomes in patients with borderline resectable pancreatic cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Alectinib Approved for ALK-Positive Adjuvant NSCLC Alectinib Approved for ALK-Positive Adjuvant NSCLC
The approval makes alectinib the first ALK inhibitor approved for early-stage NSCLC.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

ICI Tx in MS Patients With Comorbid Cancer: Reassuring Data ICI Tx in MS Patients With Comorbid Cancer: Reassuring Data
There is no increased relapse risk in patients with multiple sclerosis and comorbid cancer who are taking checkpoint inhibitor therapy, results of a small study suggest.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 19, 2024 Category: Cancer & Oncology Tags: Neurology & Neurosurgery News Source Type: news

New Screening Protocol May Improve Prostate Cancer Detection New Screening Protocol May Improve Prostate Cancer Detection
However, it ' s not yet clear whether a new three-phase screening intervention, which incorporates PSA test, a four-kallikrein panel, and MRI, will reduce prostate cancer mortality.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 19, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Clinical Summary Source Type: news

Colonoscopy With CADe Fails to Improve ADR in Real-World Colonoscopy With CADe Fails to Improve ADR in Real-World
Although CADe did not increase burden of colonoscopy, real-world adenoma detection rates cast doubt on the generalizability of positive findings from randomized trials, according to a meta-analysis.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 19, 2024 Category: Cancer & Oncology Tags: Gastroenterology News Source Type: news

How Long Should Active Surveillance Last? How Long Should Active Surveillance Last?
Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 19, 2024 Category: Cancer & Oncology Tags: Urology News Source Type: news